JOP20220242A1 - أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3 - Google Patents
أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3Info
- Publication number
- JOP20220242A1 JOP20220242A1 JOP/2022/0242A JOP20220242A JOP20220242A1 JO P20220242 A1 JOP20220242 A1 JO P20220242A1 JO P20220242 A JOP20220242 A JO P20220242A JO P20220242 A1 JOP20220242 A1 JO P20220242A1
- Authority
- JO
- Jordan
- Prior art keywords
- masp
- nucleic acids
- acids encoding
- specifically binding
- antibodies specifically
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 101001055956 Homo sapiens Mannan-binding lectin serine protease 1 Proteins 0.000 abstract 2
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000002411 adverse Effects 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y25/00—Nanomagnetism, e.g. magnetoimpedance, anisotropic magnetoresistance, giant magnetoresistance or tunneling magnetoresistance
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01F—COMPOUNDS OF THE METALS BERYLLIUM, MAGNESIUM, ALUMINIUM, CALCIUM, STRONTIUM, BARIUM, RADIUM, THORIUM, OR OF THE RARE-EARTH METALS
- C01F17/00—Compounds of rare earth metals
- C01F17/20—Compounds containing only rare earth metals as the metal element
- C01F17/206—Compounds containing only rare earth metals as the metal element oxide or hydroxide being the only anion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/77—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/08—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials
- C09K11/77—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals
- C09K11/7728—Luminescent, e.g. electroluminescent, chemiluminescent materials containing inorganic luminescent materials containing rare earth metals containing europium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01F—MAGNETS; INDUCTANCES; TRANSFORMERS; SELECTION OF MATERIALS FOR THEIR MAGNETIC PROPERTIES
- H01F1/00—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties
- H01F1/0036—Magnets or magnetic bodies characterised by the magnetic materials therefor; Selection of materials for their magnetic properties showing low dimensional magnetism, i.e. spin rearrangements due to a restriction of dimensions, e.g. showing giant magnetoresistivity
- H01F1/0045—Zero dimensional, e.g. nanoparticles, soft nanoparticles for medical/biological use
- H01F1/0054—Coated nanoparticles, e.g. nanoparticles coated with organic surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/50—Solid solutions
- C01P2002/52—Solid solutions containing elements as dopants
- C01P2002/54—Solid solutions containing elements as dopants one element only
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2002/00—Crystal-structural characteristics
- C01P2002/80—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70
- C01P2002/84—Crystal-structural characteristics defined by measured data other than those specified in group C01P2002/70 by UV- or VIS- data
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/60—Particles characterised by their size
- C01P2004/64—Nanometer sized, i.e. from 1-100 nanometer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
يتعلق الاختراع الحالي بأجسام مضادة وتركيبات مثبطة لـ MASP-3 تشتمل على مثل هذه الأجسام المضادة للاستخدام في تثبيط التأثيرات غير الملائمة لتنشيط المتمم المعتمد على MASP-3.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662369674P | 2016-08-01 | 2016-08-01 | |
US201662419420P | 2016-11-08 | 2016-11-08 | |
US201762478336P | 2017-03-29 | 2017-03-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20220242A1 true JOP20220242A1 (ar) | 2023-01-30 |
Family
ID=61073545
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2017/0154A JOP20170154B1 (ar) | 2016-08-01 | 2017-07-03 | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
JOP/2022/0245A JOP20220245A1 (ar) | 2016-08-01 | 2022-10-03 | أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة |
JOP/2022/0242A JOP20220242A1 (ar) | 2016-08-01 | 2022-10-03 | أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3 |
JOP/2022/0241A JOP20220241A1 (ar) | 2016-08-01 | 2022-10-03 | أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3 |
JOP/2022/0244A JOP20220244A1 (ar) | 2016-08-01 | 2022-10-03 | أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة |
JOP/2022/0243A JOP20220243A1 (ar) | 2016-08-01 | 2022-10-03 | أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2017/0154A JOP20170154B1 (ar) | 2016-08-01 | 2017-07-03 | تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة |
JOP/2022/0245A JOP20220245A1 (ar) | 2016-08-01 | 2022-10-03 | أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2022/0241A JOP20220241A1 (ar) | 2016-08-01 | 2022-10-03 | أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3 |
JOP/2022/0244A JOP20220244A1 (ar) | 2016-08-01 | 2022-10-03 | أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة |
JOP/2022/0243A JOP20220243A1 (ar) | 2016-08-01 | 2022-10-03 | أجسام مضادة ترتبط تحديداً بـ masp-3 لعلاج أمراض واضطرابات متنوعة |
Country Status (25)
Country | Link |
---|---|
US (4) | US10639369B2 (ar) |
EP (1) | EP3490603A4 (ar) |
JP (3) | JP6971306B2 (ar) |
KR (3) | KR102553777B1 (ar) |
CN (4) | CN116333147A (ar) |
AU (4) | AU2017306069B2 (ar) |
BR (1) | BR112019001247A2 (ar) |
CA (3) | CA3173979A1 (ar) |
CL (1) | CL2019000230A1 (ar) |
CO (1) | CO2019001212A2 (ar) |
CR (1) | CR20190105A (ar) |
CU (1) | CU24568B1 (ar) |
EC (1) | ECSP19015192A (ar) |
GE (1) | GEP20247593B (ar) |
IL (3) | IL298689B2 (ar) |
JO (6) | JOP20170154B1 (ar) |
MA (1) | MA45798A (ar) |
MX (3) | MX2019000965A (ar) |
PE (1) | PE20190389A1 (ar) |
PH (1) | PH12019500204A1 (ar) |
SA (1) | SA519400950B1 (ar) |
SG (3) | SG10202010279YA (ar) |
TW (4) | TW202214689A (ar) |
UY (1) | UY37349A (ar) |
WO (1) | WO2018026722A1 (ar) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
CA3053818A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders |
EP3814374A4 (en) * | 2018-05-25 | 2022-03-09 | Achillion Pharmaceuticals, Inc. | BIOMARKERS OF NEPHROPATHY ASSOCIATED WITH THE ALTERNATIVE COMPLEMENT PATHWAY |
KR20210057086A (ko) | 2018-09-06 | 2021-05-20 | 아칠리온 파르마세우티칼스 인코포레이티드 | 다니코판의 형태체 형태 |
WO2020051532A2 (en) | 2018-09-06 | 2020-03-12 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
BR112021005506A2 (pt) | 2018-09-25 | 2021-06-15 | Achillion Pharmaceuticals, Inc. | formas mórficas de inibidores de fator complementar d |
CN110244053B (zh) * | 2019-05-09 | 2022-03-11 | 北京大学第三医院(北京大学第三临床医学院) | 用于诊断狼疮肾炎并肺动脉高压疾病的分子标志物及其用途 |
CN112812182B (zh) * | 2019-11-15 | 2023-01-06 | 深圳宾德生物技术有限公司 | 一种靶向fgfr4的单链抗体、嵌合抗原受体、嵌合抗原受体t细胞及其制备方法和应用 |
CA3161701A1 (en) * | 2020-01-21 | 2021-07-29 | Zhaoli LI | Semg2 antibody and use thereof |
CA3189666A1 (en) * | 2020-08-18 | 2022-02-24 | William Jason Cummings | Monoclonal antibodies, compositions and methods for detecting complement factor d |
CN112950324B (zh) * | 2021-03-15 | 2022-06-03 | 重庆邮电大学 | 一种知识图谱辅助的成对排序个性化电商推荐方法及系统 |
CN115304670A (zh) * | 2021-05-07 | 2022-11-08 | 华南农业大学 | 一种猫冠状病毒核衣壳蛋白的鼠源单克隆抗体及其编码基因和应用 |
WO2023173036A2 (en) * | 2022-03-10 | 2023-09-14 | Omeros Corporation | Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
EP0672142B1 (en) | 1992-12-04 | 2001-02-28 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
US6074642A (en) * | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
US7273925B1 (en) | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
US20040031072A1 (en) * | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
CA2391402A1 (en) | 1999-12-02 | 2001-06-07 | Jens Christian Jensenius | Masp-3, a complement-fixing enzyme, and uses for it |
SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
ES2601143T3 (es) | 2002-07-19 | 2017-02-14 | Omeros Corporation | Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos |
US20040115194A1 (en) * | 2002-09-06 | 2004-06-17 | Yi Wang | Method of treatment of asthma using antibodies to complement component C5 |
AU2004216176B2 (en) | 2003-02-21 | 2008-04-03 | Genentech, Inc. | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
DE102004017370A1 (de) | 2004-04-08 | 2005-10-27 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | PUFA-PKS Gene aus Ulkenia |
US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007024715A2 (en) | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
CA2685714C (en) | 2007-05-31 | 2016-04-12 | University Of Washington | Inducible mutagenesis of target genes |
AU2010272483B2 (en) | 2009-07-17 | 2016-07-21 | Omeros Corporation | MASP isoforms as inhibitors of complement activation |
EP2462161B1 (en) * | 2009-08-06 | 2017-03-08 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
US8163283B2 (en) * | 2009-09-03 | 2012-04-24 | Vancouver Biotech Ltd. | Monoclonal antibodies against gonadotropin-releasing hormone receptor |
MX336682B (es) * | 2010-03-05 | 2016-01-27 | Hoffmann La Roche | Anticuerpos contra csf-1r humanos y usos de los mismos. |
US20120122107A1 (en) | 2010-11-16 | 2012-05-17 | Aarhus Universitet | Homeostatic multidomain protein, and uses for it |
CN107011443B (zh) * | 2011-05-04 | 2021-04-30 | 奥默罗斯公司 | 用于抑制masp-2依赖的补体活化的组合物 |
SI2833907T1 (en) * | 2012-04-06 | 2018-07-31 | Omeros Corporation | COMPOSITION AND METHODS OF INJECTION OF MASP-1 AND / OR MASP-3 FOR TREATMENT OF PAROXYSIMAL NIGHT CHEMOGLOBINURIA |
BR112014031522A2 (pt) * | 2012-06-18 | 2017-08-01 | Omeros Corp | métodos para inibir a ativação de complemento dependente de masp-3, para inibir a ativação de complemento dependente de masp-2 e para fabricar um medicamento |
ES2760023T3 (es) * | 2013-02-20 | 2020-05-12 | Univ Pennsylvania | Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado |
AU2014248515B2 (en) * | 2013-03-13 | 2019-03-07 | Prothena Biosciences Limited | Tau immunotherapy |
KR102448454B1 (ko) * | 2014-01-29 | 2022-09-28 | 다나-파버 캔서 인스티튜트 인크. | Muc1-c/세포외 도메인 (muc1-c/ecd)에 대한 항체 |
-
2017
- 2017-07-03 JO JOP/2017/0154A patent/JOP20170154B1/ar active
- 2017-07-30 TW TW110149485A patent/TW202214689A/zh unknown
- 2017-07-30 TW TW110149487A patent/TWI820555B/zh active
- 2017-07-30 TW TW106125649A patent/TWI756248B/zh active
- 2017-07-30 TW TW112116731A patent/TW202334243A/zh unknown
- 2017-07-31 GE GEAP201715019A patent/GEP20247593B/en unknown
- 2017-07-31 MA MA045798A patent/MA45798A/fr unknown
- 2017-07-31 WO PCT/US2017/044714 patent/WO2018026722A1/en active Application Filing
- 2017-07-31 SG SG10202010279YA patent/SG10202010279YA/en unknown
- 2017-07-31 BR BR112019001247A patent/BR112019001247A2/pt active Search and Examination
- 2017-07-31 CA CA3173979A patent/CA3173979A1/en active Pending
- 2017-07-31 JP JP2019505253A patent/JP6971306B2/ja active Active
- 2017-07-31 CN CN202210980626.8A patent/CN116333147A/zh active Pending
- 2017-07-31 MX MX2019000965A patent/MX2019000965A/es unknown
- 2017-07-31 CN CN202210979607.3A patent/CN116327918A/zh active Pending
- 2017-07-31 CN CN201780047995.9A patent/CN109715209B/zh active Active
- 2017-07-31 CN CN202210979606.9A patent/CN116333146A/zh active Pending
- 2017-07-31 EP EP17837477.3A patent/EP3490603A4/en active Pending
- 2017-07-31 IL IL298689A patent/IL298689B2/en unknown
- 2017-07-31 KR KR1020227010749A patent/KR102553777B1/ko active IP Right Grant
- 2017-07-31 SG SG11201900606VA patent/SG11201900606VA/en unknown
- 2017-07-31 CA CA3031980A patent/CA3031980C/en active Active
- 2017-07-31 KR KR1020227010743A patent/KR102624948B1/ko active IP Right Grant
- 2017-07-31 PE PE2019000261A patent/PE20190389A1/es unknown
- 2017-07-31 IL IL264592A patent/IL264592B2/en unknown
- 2017-07-31 CR CR20190105A patent/CR20190105A/es unknown
- 2017-07-31 US US15/665,030 patent/US10639369B2/en active Active
- 2017-07-31 AU AU2017306069A patent/AU2017306069B2/en active Active
- 2017-07-31 KR KR1020197005706A patent/KR102382804B1/ko active IP Right Grant
- 2017-07-31 SG SG10202010277SA patent/SG10202010277SA/en unknown
- 2017-07-31 CU CU2019000006A patent/CU24568B1/es unknown
- 2017-07-31 IL IL298690A patent/IL298690B2/en unknown
- 2017-07-31 CA CA3122348A patent/CA3122348A1/en active Pending
- 2017-08-01 UY UY0001037349A patent/UY37349A/es active IP Right Grant
-
2019
- 2019-01-22 MX MX2023000482A patent/MX2023000482A/es unknown
- 2019-01-22 MX MX2023000525A patent/MX2023000525A/es unknown
- 2019-01-23 SA SA519400950A patent/SA519400950B1/ar unknown
- 2019-01-28 PH PH12019500204A patent/PH12019500204A1/en unknown
- 2019-01-29 CL CL2019000230A patent/CL2019000230A1/es unknown
- 2019-02-12 CO CONC2019/0001212A patent/CO2019001212A2/es unknown
- 2019-02-28 EC ECSENADI201915192A patent/ECSP19015192A/es unknown
-
2020
- 2020-04-01 US US16/837,600 patent/US10745274B1/en active Active
- 2020-06-23 US US16/909,578 patent/US11027015B2/en active Active
- 2020-07-08 AU AU2020204551A patent/AU2020204551B2/en active Active
- 2020-10-06 AU AU2020250188A patent/AU2020250188B2/en active Active
-
2021
- 2021-04-27 US US17/241,628 patent/US11883493B2/en active Active
- 2021-11-01 JP JP2021178522A patent/JP7350822B2/ja active Active
- 2021-11-01 JP JP2021178521A patent/JP7350821B2/ja active Active
-
2022
- 2022-10-03 JO JOP/2022/0245A patent/JOP20220245A1/ar unknown
- 2022-10-03 JO JOP/2022/0242A patent/JOP20220242A1/ar unknown
- 2022-10-03 JO JOP/2022/0241A patent/JOP20220241A1/ar unknown
- 2022-10-03 JO JOP/2022/0244A patent/JOP20220244A1/ar unknown
- 2022-10-03 JO JOP/2022/0243A patent/JOP20220243A1/ar unknown
- 2022-10-17 AU AU2022256090A patent/AU2022256090A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JOP20220242A1 (ar) | أحماض نووية تشفر أجسام مضادة ترتبط تحديدا بـ masp-3 | |
PH12017502180A1 (en) | Tau-binding antibodies | |
TN2018000276A1 (en) | Inhibitors of receptor-interacting protein kinase 1. | |
EA201891366A1 (ru) | Гуманизированные антитела против cd73 | |
EP3750907A3 (en) | Raav-based compositions and methods for treating amyotrophic lateral sclerosis | |
MX2018000147A (es) | Moleculas de anticuerpo que se unen al grupo de diferenciacion 45 (cd45). | |
EP3725811A3 (en) | Compositions for inhibiting masp-2 dependent complement activation | |
EA201691916A1 (ru) | Биарильные ингибиторы киназы | |
MX2020005213A (es) | Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos. | |
PH12017502207A1 (en) | Tau-binding antibodies | |
MX2017001290A (es) | Composicion para el tratamiento de telas que comprende una nanoemulsion de polimero de aminosiloxano. | |
PH12019500789A1 (en) | Anti-c1s antibodies and methods of use thereof | |
MX2018003183A (es) | Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas. | |
EA201691397A1 (ru) | Хинолиновые ингибиторы киназы | |
EA201890810A1 (ru) | Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение | |
BR112018012304A2 (pt) | composições e métodos para diminuir expressão de tau | |
PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
EA201691549A1 (ru) | Ариллактамные ингибиторы киназы | |
PH12017502277A1 (en) | Multi-specific binding proteins | |
TN2018000057A1 (en) | Compounds useful for inhibiting ror-gamma-t. | |
TN2018000180A1 (en) | Polypeptides inhibiting cd40l | |
MX2019005933A (es) | Polipeptidos biespecificos para gitr y ctla-4. | |
MX2019002185A (es) | Composiciones y metodos relacionados con la inhibicion de la señalizacion de rangos. | |
MX2017003949A (es) | Derivados peptidicos novedosos y sus usos. | |
MX2018009218A (es) | Anticuerpos de cgrp y sus usos. |